BioGaia Drop especially is renowned as the only clinically proven probiotics that can prevent infantile colic. Other benefits include management of regurgitation, constipation, functional abdominal pain, acute gastroenteritis and, support of gastrointestinal health and management of antibiotic- associated side-effects. On adults its benefits on colonisation and effects on the immune system, benefits on gastrointestinal disorders and its safety aspects is well documented.
Their benefits and safety in use for all ages is documented and supported by series of scientific and clinical studies. To date 266 clinical studies have been conducted on almost 22,634 individuals whereof 85 studies are on 0 – 3 years old in 10,931 subjects. The results are published in more than 90 articles in scientific journals.
World leader in probiotics
BioGaia is a world leader in probiotics thanks to over 20 years experience in the field of probiotics. Over the years BioGaia have created a global network of leading, independent researchers and specialists, in-house experts and commercial partners worldwide.
Organisation
Headquarters, with executive management, administrative functions and marketing and sales are based in Stockholm. Product development and departments for production and quality control are based in Lund. Research, quality control and product development are also perused in Raleigh, North Carolina, USA. Sales offices are also based in Hiroshima and Shanghai.
The class B share of BioGaia is quoted on the Mid Cap list of the Nordic Exchange Stockholm.
Products
DROP
Summary of clinical studies: Infants and Toddlers
*Download the PDF to view
*Download the PDF to view
BioGaia L. reuteri effective in the prevention of infantile colic
This randomised, controlled, single-blinded, multi-centre study was performed to evaluate the efficacy of L. reuteri DSM 17938 in reducing parental discomfort due to infantile colic in a population of otherwise healthy infants.
105 infants aged less than 10 days were randomly assigned to receive five drops per day (10^8 CFU) of L. reuteri with vitamin D (n=51), or vitamin D only (n=54), for three months.
Primary endpoint was measured as use of pain relieving agents. Secondary endpoints was measured as percentage of infants that switched from an exclusive breastfeeding to partial or exclusive formula feeding and number of calls to the paediatricians and number of visits at paediatricians’ ambulatories due to infantile colic.
The results showed:
Significantly less use of pain relieving agents in infants supplemented with L. reuteri compared to control group
• 75% less use of simethicone
• 96% less use of cimetropium bromide
This study adds evidence to the previous study with L. reuteri and the beneficial effects in the prevention of infantile colic
Reference
Savino F, Ceratto S, Poggi E, Cartosio ME, Cordero di Montezemolo L, Giannattasio A. Preventive effects of oral probiotic on infantile colic: a prospective, randomised, blinded, controlled trial using Lactobacillus reuteri DSM 17938. Beneficial Microbes. 2015 Jan 1;6(3):245-51. doi: 10.3920/BM2014.0090.
*Download the PDF to view
CHEWABLES
Summary of Clinical Studies
*Download the PDF to view
*Download the PDF to view
*Download the PDF to view
BioGaia Drops
BioGaia Drops with Vitamin D3
BioGaia Protectis Powder
BioGaia Probiotic Chewable Tablets
BioGaia Prodentis